EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats

Xiumei Zhu, Yawen Zhang iD

Pain Research and Management · 2026-01 · 2026 (1)

DOI: 10.1155/prm/5536335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Research and Management, online erschienen am 17.08.2026. Verfasst von Xiumei Zhu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Guannan County First People's Hospital, Lianyungang 223500, China. Hauptthemen laut MEDLINE: MicroRNAs, Proto-Oncogene Proteins c-akt, Neuralgia, Inflammation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The analgesic effects of esketamine have been reported. MiR‐153–3p is a central player in multiple pathologies of neural injury. The potential interplay between them remains unclear.

Objective

This study investigated whether the analgesic effects of esketamine in neuropathic pain were mechanistically linked to miR‐153–3p. Materials and Methods Neuropathic pain was induced in rats through chronic constriction injury (CCI) of the sciatic nerve, followed by esketamine administration. Pain hypersensitivity was assessed by dynamic changes in paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). MiR‐153–3p expression was manipulated via intrathecal injection of lentiviral‐delivered miR‐153–3p mimic. RT‐qPCR was employed for analysis of miR‐153–3p expression and AKT3 mRNA levels. Proinflammatory cytokine levels were quantified by ELISA, while protein expression was detected using Western blot. The interaction between miR‐153–3p and AKT3 was verified by RIP and luciferase reporter assays.

Results

Esketamine alleviated CCI‐induced neuropathic pain by elevating PWMT and PWTL. Esketamine also reduced proinflammatory cytokine release. MiR‐153–3p was significantly reduced in CCI rats, and esketamine administration effectively reversed its decline. MiR‐153–3p upregulation suppressed pain hypersensitivity and proinflammatory cytokines. AKT3 was a target of miR‐153–3p. AKT3 knockdown abolished the effect of MiR‐153–3p inhibition on esketamine protection.

Conclusion

Esketamine mitigated neuropathic pain and reduced proinflammatory cytokine release through the miR‐153–3p/AKT3 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsProto-Oncogene Proteins c-aktNeuralgiaInflammationAnalgesicsAnimalsMaleRatsRats, Sprague-DawleyHyperalgesia

Stichwörter der Autor:innen

esketamineinflammationmiR-153–3pneuropathic pain

Substanzen

MicroRNAsProto-Oncogene Proteins c-aktAkt3 protein, ratAnalgesics

Autor:innen und Institutionen

  • Department of Anesthesiology, Guannan County First People's Hospital, Lianyungang 223500, China.
  • Department of Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China, hebmu.edu.cn.

ORCID-Profile: Yawen Zhang

Zitieren

APA

Zhu, X., & Zhang, Y. (2026). Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats. Pain Research and Management, 2026(1). https://doi.org/10.1155/prm/5536335

Vancouver

Zhu X, Zhang Y. Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats. Pain Research and Management. 2026;2026(1). doi:10.1155/prm/5536335

BibTeX
@article{Zhu2026,
  author = {Zhu, Xiumei and Zhang, Yawen},
  title = {Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats},
  journal = {Pain Research and Management},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/prm/5536335}
}
Kostenlos starten →